SecBot SecBot
SECBOTREPLAY Home › Report › CPRX

CPRX · Catalyst Pharmaceuticals stockholders approved the $31.50/share…

CATALYST PHARMACEUTICALS, INC. · 8-K filed Jul 8, 2026 at 17:29 ET

At the news

BULLISHIMPACT 6/10

8-K filed Jul 8, 2026 at 17:29 ET

Catalyst Pharmaceuticals stockholders approved the $31.50/share all-cash acquisition by Angelini Pharma at the July 8, 2026 special meeting, with over 79% of outstanding shares voting in favor. The compensation proposal for executives was rejected on a non-binding advisory basis, but this does not affect deal closure. All directors have indicated their intent to resign effective at merger closing. The merger now has cleared its key stockholder condition.

  • Merger proposal approved by holders of 97,340,180 shares For (79.5% of outstanding) vs. 1,143,815 Against and 242,616 Abstentions.
  • Advisory compensation proposal NOT approved (30,504,686 For, 67,486,884 Against) but non-binding and not a condition to closing.
  • All seven directors intend to resign effective at merger closing; no disagreements cited.
  • 80.6% of outstanding shares were present or represented at the special meeting.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access